Reduced dementia incidence after varicella zoster vaccination in Wales 2013–2020

Christian Schnier1 | Janet Janbek2 | Richard Lathe1 | Jürgen Haas1

1 Division of Infection Medicine, University of Edinburgh Medical School, Edinburgh, UK
2 Danish Dementia Research Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

Abstract

Introduction: Chronic infection with herpes viruses is a potential contributing factor to the development of dementia. The introduction of nationwide shingles (varicella zoster) vaccination in Wales might therefore be associated with reduced incident dementia.

Methods: We analyzed the association of shingles vaccination with incident dementia in Wales between 2013 and 2020 using retrospectively collected national health data.

Results: Vaccinated individuals were at reduced risk of dementia (adjusted hazard ratio: 0.72; 95% confidence interval: 0.69 to 0.75). The association was not modified by a reduction in shingles diagnosis and was stronger for vascular dementia than for Alzheimer’s disease. Vaccination was also associated with a reduction in several other diseases and all-cause mortality.

Discussion: Our study shows a clear association of shingles vaccination with reduced dementia, consistent with other observational cohort studies. The association may reflect selection bias with people choosing to be vaccinated having a higher healthy life expectancy.

KEYWORDS
Alzheimer’s disease, shingles, vaccine, vascular dementia

1 INTRODUCTION

Research into the association of vaccination with dementia serves several purposes. Any association would highlight the contribution of the immune system and/or pathogens to the disease progression to dementia and would allow a deeper understanding of the natural history of dementia. In addition, vaccination strategies could be developed to cost-effectively reduce the rate of dementia.

Several observational cohort and case-control studies have shown a reduction in dementia rates post-vaccination. Twenty years ago Verreault et al. reported that vaccine exposure (diphtheria/tetanus, polio, influenza) was associated with a 25% to 60% reduction in later Alzheimer’s disease (AD) development. Klinger et al. demonstrated a significantly reduced risk of developing AD in bladder cancer patients exposed to repeated intravesical applications of Bacillus Calmette–Guérin (BCG) vaccine, especially in the population aged 75 years and older. Scherrer et al. showed a significantly reduced rate of dementia in people vaccinated with Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) and shingles vaccination compared to those not vaccinated using data from two American disease registers (Veterans Health Administration and MarketScan). Liu et al. found a reduced dementia rate in chronic kidney disease patients vaccinated with influenza vaccine using data from the National Health Insurance Research Database of Taiwan. However, observational studies to
ascertain vaccine efficacy are not easy to interpret, and, to our knowledge, no vaccine, whether specific for dementia or with a primary target other than dementia, has been proven in a clinical trial to be efficient in preventing dementia.

Chronic infection with human herpes viruses (HHVs) has recently been highlighted as a potential contributing factor to the development of dementia, especially AD. Population-wide observational cohort studies indicate a moderate to non-existing positive association of a diagnosis of HHV infection with incident dementia, and some studies point to a potential mediating role of antitherpetic medication. In addition to the registry-based observational cohort studies, several cohort studies have been published that investigated associations of HHV infection with incident dementia.

HHV3, also known as varicella zoster virus (VZV), is generally acquired early in childhood when it causes chickenpox, but the virus persists lifelong and can re-emerge in the elderly as shingles, and has also been associated with postherpetic neuralgia, encephalitis and/or meningitis, and respiratory disease. To reduce the effects of HHV3 re-emergence in the elderly, national vaccination strategies have been implemented in the UK and elsewhere. In Wales, national shingles vaccination has been conducted since 2013, with the aim to vaccinate people aged 70 years, and a catch-up vaccination at age 79 for those not vaccinated at age 70. Shingles vaccination is part of the Public Health Wales Vaccine Preventable Disease Programme funded by Public Health England; the vaccination is free for anybody registered with the National Health Service. For the year 2019, published records show a vaccine uptake of between 40% (70-year-olds) and 73% (75-year-olds). Until 2018 the only available shingles vaccine in Wales was an attenuated live HHV3 vaccine (Zostavax); since June 2018 a small proportion of the Welsh population received recombinant shingles vaccine (Shingrix).

Our objective was to analyze the association of shingles vaccination with incident dementia in Wales between 2013 and 2020. Furthermore, we analyzed whether that association was mediated by a reduction of diagnosed shingles and whether the association was different for AD than for vascular dementia (VaD).

2 MATERIAL AND METHODS

2.1 Study population and period

The study population comprised the complete population of Wales born after September 1, 1933 who were registered with a primary care provider (general practitioner [GP]) and whose GP was reporting into the Secure Anonymised Information Linkage (SAIL) Databank in Wales (approximately 80%). For each person in the study population, follow-up started with a 70th birthday at any time during the period between 2013 and 2020; however, to allow for retrospective classification of risk factors before vaccination, people were excluded who, at their 70th birthday, were not registered with a participating GP for at least 5 years. People were also excluded for whom date of birth, sex, or socioeconomic status was missing or who were diagnosed with dementia before their 70th birthday.

2.2 Classification

Vaccination status, dementia incidence, and covariates used in the analyses were classified using routinely collected health data (RCHD) in the SAIL databank. The databank holds linked information from primary care (Read V2), hospital admissions (International Classification of Diseases, 10th revision [ICD 10]), and mortality records (ICD 10), as well as registration data and information on area-based socioeconomic status (Welsh Index of Multiple Deprivation [WIMD]).

Dementia was classified using primary care diagnostic data and hospital admission data, and the first code found was used as the date of diagnosis. The codes used to classify dementia (Table S1 in supporting information) in British RCHD have been validated previously and found to be of good predictive value. Medication codes were not used because we judged that the positive predictive value for a medication code in the absence of a concurrent diagnostic code to be insufficient. Exposure to the shingles vaccine was classified using codes from the primary care records, either as a shingles (herpes zoster) vaccination (preventive procedure) or as a prescription for a shingles vaccination. The validity of the codes for shingles vaccination (Table S1) has to our knowledge not been studied, but the same data source and codes are used for national vaccine coverage reports by the Public Health Wales Vaccine Preventable Disease Programme. The attenuated live
herpes zoster vaccine used for most people in the study population is given only once; in the unusual event of a second vaccination (mostly recombinant zoster vaccine) we have taken the time of first vaccination as time of exposure. Shingles and other diseases were classified using primary care diagnostic data and hospital admission data; again, medication codes on their own were deemed to be insufficient. Care home residency between age 65 and 70 years (before follow-up) was classified using codes from the social/personal history recorded in the primary care data; previous research has shown that recording of care home residence is limited in primary care records. Frailty was classified using a summary measure of 5 years of GP data between the ages of 65 and 70, including 36 “deficits” (clinical signs, symptoms, diseases, and disabilities). Finally, we included 11 comorbidities that make up the Charlson Comorbidity Index (CCI), again classified over 5 years of GP data between the ages of 65 and 70. In contrast to the calculation of the electronic frailty index (eFI) as published, and the CCI as published, in our study a diagnosis of dementia was excluded.

2.3 Statistical analysis

We first identified factors associated with vaccination and with incident dementia in the scientific literature. We then analyzed the association of multiple putative risk factors with shingles vaccination in several univariable Cox proportional hazard models (CoxPH). We used factors associated with vaccination in addition to other reported risk factors for dementia in several univariable CoxPH models on the hazard of incident dementia. We used fractional polynomials to find the best transformation for the eFI and added it to the model as a continuous variable; all other variables were categorical. Year of birth was categorized as < 1943 and later because those born before 1943 were only eligible for the catch-up vaccination. All survival analysis models were stratified by that category to allow for different underlying hazard functions. Finally, we modeled the association of shingles vaccination with incident dementia in a multivariable CoxPH model in which shingles vaccination was included as time-dependent variable. To adjust for correlation between patients of the same GP practice, we added the practice number as a random effect (frailty model). In all survival models, people were followed up from their 70th birthday to the first diagnosis of dementia or censoring (death or the end of the study period in January 2020).

To analyze whether the association was different for AD than for VaD, we replaced the dementia outcome with the more specific outcome of either AD or VaD. In these models we additionally censored observations at the time of any other dementia.

To analyze the association of vaccination with shingles incidence, we used a similar CoxPH model with shingles vaccination included as a time-dependent variable and a shingles diagnosis as the outcome variable. In that model, to avoid effects of an increased shingles risk in people with dementia, we additionally censored observations at the time of dementia.

To analyze whether the association of vaccination with dementia was mediated by a reduction in shingles incidence in those vaccinated, we modeled the association of shingles vaccination with incident dementia in a multivariable CoxPH model, with shingles vaccination and shingles diagnosis included as time-dependent variables. This created five different exposure categories: (1) not vaccinated, no shingles diagnosis (every person at the start of follow-up); (2) not vaccinated, shingles diagnosed; (3) vaccinated, no shingles diagnosed; (4) first vaccinated then shingles diagnosed; and (5) first shingles diagnosis then vaccinated.

To test, whether the association of the shingles vaccine was specific for dementia, we additionally analyzed the association of vaccination with cancer, myocardial infarction (MI), stroke, hip fracture, and all-cause mortality. These outcomes were chosen because they were common outcomes and represented outcomes that were not primarily of infectious etiology and therefore less likely to be associated with the vaccination. We again used a CoxPH model including vaccination as a time-dependent variable, stratified by year of birth adjusting for the same confounders and for the correlation between patients of the same practice. Furthermore, we compared the underlying causes of death for those who died during the follow-up period.

2.4 Governance

Use of anonymized linked data from SAIL was granted under Information Governance Review Panel (IGRP) 0938. All data management and analysis were performed on the secure research platform from SAIL.

3 RESULTS

The study population comprised 336,341 people (total of 2,284,603 person-years of follow-up), of whom 161,428 (48%) were born after 1943 and 162,142 (48%) were male. During follow-up, 155,972 (46%) were exposed to the vaccine, 53,822 (16%) died, and 18,570 (5.5%) were diagnosed with dementia. People less likely to be vaccinated were female; had been diagnosed with rheumatic disease, perivascular disease, MI, liver disease, cerebrovascular disorders, or coronary heart disease; were living in a care home; or were frail. Renal disease, diabetes, and chronic pulmonary disease; prior vaccination; and higher socioeconomic status were positively associated with shingles vaccination (Table 1).

Most people vaccinated between 2013 and 2019 were vaccinated at age 70 years; a further group of people were vaccinated between age 77 and 79. Especially over the later years, vaccinations at ages other than the suggested 70 and 79 were more common (Figure S1 in supporting information). Accordingly, the vaccination rate differed widely between those born before and after 1943.

Compared to people not vaccinated during follow-up, people who were exposed to the shingles vaccine were at lower risk of being diagnosed with dementia (adjusted hazard ratio [aHR]: 0.72; 95% confidence interval [CI]: 0.69–0.75; univariable HR: 0.78; 95% CI: 0.75–0.81; Figure 1A and Table S2 in supporting information).
### TABLE 1  
Association of risk factors with exposure to shingles vaccine

| Variable                          | Level      | Total N   | Vaccinated N (%) | Hazard ratio (95% CI) a |
|-----------------------------------|------------|-----------|------------------|-------------------------|
| Sex                               | Female     | 174,317   | 81,064 (47%)     | 0.95 (0.95 to 0.96)     |
| Born after 1943                   | Yes        | 161,476   | 90,012 (56%)     | 26.63 (25.99 to 27.29)  |
| WIMDb b                           | 1          | 54,950    | 22,576 (41%)     | 1.00 (ref)              |
|                                   | 2          | 65,067    | 27,855 (43%)     | 1.04 (1.02 to 1.06)     |
|                                   | 3          | 70,425    | 31,499 (45%)     | 1.08 (1.07 to 1.1)      |
|                                   | 4          | 67,269    | 33,150 (49%)     | 1.22 (1.2 to 1.24)      |
|                                   | 5          | 78,748    | 40,947 (52%)     | 1.28 (1.26 to 1.3)      |
| Frailty                           | Fit        | 255,118   | 119,192 (47%)    | 1.00 (ref)              |
|                                   | Mild       | 69,379    | 32,233 (46%)     | 1.08 (1.07 to 1.09)     |
|                                   | Moderate   | 10,942    | 4291 (39%)       | 0.99 (0.96 to 1.02)     |
|                                   | Severe     | 1020      | 310 (30%)        | 0.85 (0.76 to 0.95)     |
| Care home                         | Yes        | 432       | 89 (21%)         | 0.57 (0.46 to 0.7)      |
| Prior vaccination                 | Yes        | 264,454   | 141,164 (53%)    | 3.01 (2.96 to 3.06)     |
| Diabetes                          | Yes        | 47,411    | 22,232 (47%)     | 1.13 (1.11 to 1.14)     |
| Cancer                            | Yes        | 23,987    | 11,085 (46%)     | 1.07 (1.05 to 1.1)      |
| Cerebrovascular disease           | Yes        | 10,690    | 4228 (40%)       | 0.87 (0.84 to 0.9)      |
| Chronic obstructive pulmonary disease | Yes   | 37,902    | 18,449 (49%)     | 1.13 (1.11 to 1.14)     |
| Chronic heart disease             | Yes        | 4858      | 1815 (37%)       | 0.89 (0.85 to 0.94)     |
| Chronic liver disease             | Yes        | 1000      | 370 (37%)        | 0.95 (0.85 to 1.05)     |
| Myocardial infarction             | Yes        | 5514      | 2231 (40%)       | 0.83 (0.79 to 0.86)     |
| Peptic ulcer                      | Yes        | 2085      | 813 (39%)        | 0.77 (0.72 to 0.82)     |
| Periappendicitis                  | Yes        | 5695      | 2075 (36%)       | 0.84 (0.81 to 0.88)     |
| Renal disease                     | Yes        | 20,694    | 9165 (44%)       | 0.95 (0.93 to 0.97)     |
| Rheumatic disease                 | Yes        | 6444      | 2411 (37%)       | 0.77 (0.74 to 0.8)      |

aNFor sex, birth year, care home, prior vaccination, and all disease groups, the reference (HR = 1) is set to males, born before 1943, not in a care home, no prior vaccination, and people without each of the diseases, respectively.

bWelsh Index of Multiple Deprivation: level 1 is most deprived, 5 is least deprived.

Abbreviations: CI, confidence interval; HR, hazard ratio; WIMD, Welsh Index of Multiple Deprivation.

That association varied slightly with the two dementia subtypes: People exposed to the shingles vaccine were at lower risk of being diagnosed with AD (aHR: 0.81; 95% CI: 0.77–0.86) and at lower risk of being diagnosed with VaD (aHR: 0.66; 95% CI: 0.61–0.71; Figure 1A, and Tables S3 and S4 in supporting information). Shingles vaccination was associated with a substantial reduction in subsequent shingles diagnosis (aHR: 0.43; 95% CI: 0.41–0.45; Figure 2); however, we could not find any evidence that the association of shingles vaccination with dementia was mediated by a reduction in shingles diagnosis. Compared to people not vaccinated with no shingles diagnosis, those vaccinated with no shingles diagnosis had 0.71 times lower hazard (aHR: 0.71; 95% CI: 0.68–0.74), whereas those vaccinated with a subsequent diagnosis of shingles (“vaccine failures”) had a similar, 0.69 times lower hazard (aHR: 0.69; 95% CI: 0.53–0.89; Figure 1B and Table S5 in supporting information).

Compared to people not vaccinated during follow-up, people who were exposed to the shingles vaccine were at lower risk of being diagnosed with MI (aHR: 0.86; 95% CI 0.82–0.90), stroke (aHR: 0.86; 95% CI 0.82–0.91), or hip fracture (aHR: 0.55; 95% CI 0.54–0.57); there was no difference in the risk of being newly diagnosed with cancer during follow-up (aHR: 0.98; 95% CI 0.95–1.01). Similarly, people who were exposed to the shingles vaccine were at lower risk of all-cause mortality (aHR: 0.58; 95% CI 0.57–0.60; Figure 2). A purely descriptive/exploratory analysis of the underlying causes for mortality in those who died during follow-up did not reveal differences between vaccinated and non-vaccinated individuals (Figure S2 in supporting information).

#### DISCUSSION

We analyzed the association of shingles vaccination with incident dementia in those vaccinated in Wales between 2013 and 2020 in an observational cohort study using retrospectively collected national health data. People exposed to the vaccine had a 39% reduced hazard of dementia diagnosis after vaccination. This association is similar to the study by Scherrer et al. who found a 43% reduction in dementia in those vaccinated against shingles. It compares favorably to the
of vaccination with cerebrovascular health was our finding that shingles vaccination was additionally associated with a reduction of stroke incidence.

Shingles vaccination was associated with a substantial reduction in shingles incidence (aHR: 0.43), which is slightly better than the vaccine effect reported by Blom et al.30 (aHR = 0.66, 95% CI: 0.55–0.78).

However, the reduced hazard of dementia in those vaccinated against shingles was probably not mediated by a reduction in shingles incidence because the HR in people not vaccinated without shingles was similar to the HR in those vaccinated without shingles, as well as the HR in those vaccinated without subsequent shingles ("vaccine failures"). This result points to a non-specific effect of shingles vaccination on dementia incidence rather than a direct effect via shingles reduction. However, our results must be interpreted carefully because the total follow-up time of people who were vaccinated and had a subsequent diagnosis of shingles was low, causing wide confidence intervals in the estimate. The low number of observations made it impossible to further stratify the population by exposure to antiviral medication. Antiherpetic medication is prescribed in the UK for people with shingles, especially immune-compromised individuals, to reduce their risk for post-herpetic neuralgia. Exposure to antiherpetic medication has been associated with incident dementia, although estimates of the reported effect size from different studies vary considerably.7,9,31

However, exposure to antiviral medication is on the (hypothetical) causal pathway of the association of shingles vaccination with dementia, so we would not expect any bias from the exposure to antiviral medication in our study.

People exposed to the shingles vaccine were at lower risk of all-cause mortality (aHR: 0.58), MI, (aHR: 0.86), stroke (aHR: 0.86), and hip fracture (aHR: 0.55)—but not cancer (aHR: 0.98)—and the aHRs were similar in size to the aHR for the association of vaccination with dementia. This result could indicate a non-specific effect of the shingles vaccination.32

We have carefully considered the possibility of a potential mechanism that explains our findings, particularly in AD. There has been escalating interest in the possibility that AD is triggered by infection34 and that the signature protein of AD brain, Aβ peptide, has antimicrobial activity, and thus may be a consequence rather
than a cause of AD. One potential interpretation of our results is therefore that the live attenuated VZV vaccine acts as an adjuvant that plays a role in the immune responses against microbes. This interpretation is supported by (1) documented immune cross-protection in which infection with one pathogen can alleviate the disease caused by a second unrelated pathogen, and (2) precedent: an immune adjuvant alone (alum) was reported to retard AD development, and a potent adjuvant vaccine (killed attenuated Mycobacterium, BCG) was reported to reduce AD rates in bladder cancer patients. The adjuvant theory should be considered carefully, alongside other theories, as a potential explanation for the negative association between VZV vaccination and incident dementia. However, the additional outcomes we have chosen (cancer, MI, stroke, hip fracture, and all-cause mortality) are primarily not driven by infectious pathogens, and differences in mortality were not more pronounced in diseases with a predominantly infectious etiology (e.g., respiratory diseases). Furthermore, the association we observed was stronger for VaD compared to AD. Therefore, our results might indicate a selection bias, with people getting vaccinated having a higher (healthy) life expectancy at the time of vaccination, and thus less likely to be at risk of imminent diagnosis of dementia. Indeed, non-specific vaccine effects such as lower mortality have previously been described in observational cohort studies of vaccine efficacy by Simonen et al., who attributed the association to a frailty selection bias. To control for frailty selection bias we adjusted for frailty (efI) between age 65 and 70, for care home residency, and for multiple diseases that make up the CCI. All these variables were associated with lower rates of vaccination (Table 1) and increased rates of dementia (Tables S2–S4); however, adjusting for them in the dementia model (or any of the other outcomes) did not drastically modify the estimates.

Selection bias may be the main limitation of our study. Similarly to other observational cohort studies, the reason some people were exposed to the vaccine, whereas others were not, remains unknown. Although we controlled for “frailty,” we cannot exclude with confidence that people not being vaccinated might have a lower healthier life expectancy. This observation would be supported by results from vaccine efficacy studies for Zostavax, which did not show any significant difference in mortality between those exposed to the vaccine and those exposed to a placebo. Furthermore, even though our study population was large and representative of the Welsh population, the average follow-up period was rather short. This was due to the introduction of the vaccine in 2013, which gave us a maximum follow-up time of approximately 6 years (until age 76).

5 | CONCLUSIONS

Our study shows a clear association between shingles vaccination and reduced dementia incidence, which is consistent with other observational cohort studies. As such, non-exposure to a vaccine, be it a shingles vaccine or Tdap, could potentially be used as an early warning sign of deteriorating health, and it would be interesting to analyze whether vaccine exposure could be used in predictive modeling. Although we cannot exclude a true effect, our results lead us to suspect that the association reflects frailty selection bias rather than a genuine vaccine effect. The unexpected greater association with VaD than with AD, the unexpected result that a diagnosis of shingles was not a mediating variable, the non-specific effects of vaccination on other diseases and mortality, and the fact that other vaccines such as Tdap and BCG were also associated with reduced dementia in other studies points more to a selection bias associated with vaccination than a genuine vaccine effect. We further encourage consideration of and research into potential theories that may explain the negative association with incident dementia and shed light on whether this may reflect a genuine vaccine effect. Secondary analysis of results from randomized controls trials into the efficacy of shingles vaccination might provide important insights.

ACKNOWLEDGMENTS

This work was supported by the Benter Foundation. It makes use of the Secure Anonymised Information Linkage (SAIL) Databank. We would like to acknowledge all the data providers who make anonymized data available for research.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest. CS: received funding from the Benter Foundation (to the University of Edinburgh) for research and visits to AAIC and EAN conferences. JJ: no funding to declare. RL: received funding from the Benter Foundation (to the University of Edinburgh) for research; consulting fees to himself from Life Science Capital and the University of Edinburgh; funding to attend meetings to himself from Prevention Alzheimer International Foundation (International Conference of Chronic Inflammatory Disorders – Alzheimer’s Disease), Associazione Autonoma Aderent alla SIN per le Demenze (SINDem; 7th Winter Seminar in Clinical and Experimental Research on Dementia and Neurodegenerative Disorders), Societa Italiana de Neurologia (Sin; 7th Winter Seminar in Clinical and Experimental Research on Dementia and Neurodegenerative Disorders), Deutsche Forschungs Gemeinschaft and the Psel-Alzheimer-Stiftung (2nd International Conference on Cognitive Reserve in Dementia).

JH: received funding from the Benter Foundation, BBsRC, MRC, and Wellcome Trust (to the University of Edinburgh) for research and consulting fees (to the University of Edinburgh) from Pneumagen Ltd.

REFERENCES

1. Verreault R, Laurin D, Lindsay J, De Serres G. Past exposure to vaccines and subsequent risk of Alzheimer’s disease. CMAJ 2001;165:1495-8.
2. Klinger D, Hill BL, Barda N, et al. Bladder Cancer Immunotherapy by BCG Is Associated with a Significantly Reduced Risk of Alzheimer’s Disease and Parkinson’s Disease. Vaccines 2021;9:491. https://doi.org/10.3390/vaccines9050491
3. Scherrer JF, Salas J, Wiemken TL, Jacobs C, Morley JE, Hoft DF. Lower risk for dementia following adult tetanus, diphtheria, and pertussis (Tdap) vaccination. Journals Gerontol Ser A 2021;XX:1-8. https://doi.org/10.1097/gerona/glba115
4. Liu JC, Hsu YP, Kao PF, et al. Influenza vaccination reduces dementia risk in chronic kidney disease patients: a population-based cohort study. Med (United States) 2016;95. https://doi.org/10.1097/MD.0000000000002868
5. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. *Lancet Infect Dis* 2007;7:658-66.

6. Izhaki RF, Lathe R. Herpes viruses and senile dementia: first population evidence for a causal link. *J Alzheimer’s Dis* 2018;64:363-6. https://doi.org/10.3233/JAD-180266

7. Schnier C, Janbek J, Williams L, et al. Antitherapeutic medication and incident dementia: observational cohort studies in four countries. *Eur J Neuro* 2021;28:1840-8. https://doi.org/10.1111/ejn.14795

8. Bae S, Yun SC, Kim MC, et al. Association of herpes zoster with dementia and effect of antiviral therapy on dementia: a population-based cohort study. *Eur Arch Psychiatry Clin Neurosci* 2020. https://doi.org/10.1007/s00406-020-01157-4

9. Lopatko Lindman K, Hemmingsson E, Weidung B, et al. Herpesvirus infections, antiviral treatment, and the risk of dementia—a registry-based cohort study in Sweden. *Alzheimer’s Dement Transl Res Clin Interv* 2021;7:e12119. https://doi.org/10.1002/trc.212119

10. Choi HG, Park BJ, Lim JS, Sim SY, Jung YJ, Lee SW. Herpes zoster does not increase the risk of neurodegenerative dementia: a case-control study. *Am J Alzheimers Dis Other Demen* 2021;36. https://doi.org/10.1177/15331756211006504

11. Lövheim H, Norman T, Weidung B, et al. Herpes Simplex virus, APOE ε4, and cognitive decline in old age: results from the betula cohort study. *J Alzheimer’s Dis* 2019;67:211-20. https://doi.org/10.3233/JAD-171162

12. Letenneur L, Pérès K, Fleury H, et al. Seropositivity to Herpes Simplex Virus antibodies and risk of Alzheimer’s disease: A population-based cohort study. *PLoS One* 2008;3:e3637. https://doi.org/10.1371/journal.pone.0003637

13. Linard M, Letenneur L, Garrigue I, Doize A, Dartiuges JF, Helmer C. Interaction between APOE4 and herpes simplex virus type 1 in Alzheimer’s disease. *Alzheimer’s Dement* 2020;16:200-8. https://doi.org/10.1016/j.alz.12008

14. Lopatko Lindman K, Weidung B, Olsson J, et al. A genetic signature including apolipoprotein E4 potentiates the risk of herpes simplex-associated Alzheimer’s disease. *Alzheimer’s Dement Transl Res Clin Interv* 2019;5:697-704. https://doi.org/10.1016/j.jtrci.2019.09.014

15. Sampathkumar P, Drage LA, Martin DP. Herpes zoster (Shingles) and postherpetic neuralgia. *Mayo Clin Proc* 2009;84:274-80. https://doi.org/10.4065/84.3.274

16. Welsh Government. Welsh Health Circular. 2015.

17. Public Health Wales. No Title. NatL HB Lev Shingles Dashboard 2020. https://phw.nhs.wales/data/data-sources/immunisation-and-vaccines/

18. Akkari A, Lyons R, Bandypadhyay A, et al. Analysis of factors associated with changing general practice in the first 14 years of life in Wales using linked cohort and primary care records: implications for using primary care databanks for life course research. *Int J Popul Data Sci* 2018;3. https://doi.org/10.23889/IJPDS.V3I4.818

19. Lyons RA, Hutchings R, Rodgers SE, et al. Development and use of a privacy-protecting total population record linkage system to support observational, interventional, and policy relevant research. *Lancet* 2012;380:56. https://doi.org/10.1016/s0140-6736(13)60362-1

20. Wilkinson T, Schnier C, Bush K, et al. Identifying dementia outcomes in UK Biobank: a validation study of primary care, hospital admissions and mortality data. *Eur J Epidemiol* 2019;34:557-65. https://doi.org/10.1007/s10654-019-00499-1

21. Shah SM, Carey IM, Harris T, et al. Identifying the clinical characteristics of older people living in care homes using a novel approach in a primary care database. *Age Ageing* 2010;39:617-23. https://doi.org/10.1093/ageing/afq086

22. Clegg A, Bates C, Young J, et al. Development and validation of an electronic frailty index using routine primary care electronic health record data. *Age Ageing* 2016;45:353-60. https://doi.org/10.1093/ageing/afw039

23. Khan NF, Harrison SE. Rose PW. Validity of diagnostic coding within the general practice research database: a systematic review. *Br J Gen Pract* 2010;60:199-206. https://doi.org/10.3399/bjgp10X43562

24. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet* 2020;396:413-46.

25. Iadecola C. The pathobiology of vascular dementia. *Neuron* 2013;80:844-66. https://doi.org/10.1016/j.neuron.2013.10.008

26. Lathe R, Saponova A, Kotelevtsev Y. Atherosclerosis and Alzheimer’s disease: a common cause? Inflammation, oxysterols, vasculature. *BMC Geriatr* 2014;14:1-30. https://doi.org/10.1186/1471-2318-14-36

27. Craighead. Pathology and Pathogenesis of Human Viral Disease. *Pathol Pathog Hum Viral Dis* 2000. https://doi.org/10.1016/B978-0-12-195160-3X5000-6

28. Gilden D, Cohrs RJ, Mahalingam R, Nagel MA. Varicella zoster virus vasculopathies: diverse clinical manifestations, laboratory features, pathogenesis, and treatment n.d.

29. Nagel MA, Niemeyer CS, Bubak AN. Central nervous system infections produced by varicella zoster virus. *Curr Opin Infect Dis* 2020;33:273-8. https://doi.org/10.1097/QCO.0000000000000647

30. Blom K, Yin L, Arnheim-Dahlsstrom L. Effectiveness of the herpes zoster vaccine Zostavax® in Stockholm County, Sweden. * Vaccine* 2019;37:4401-6. https://doi.org/10.1016/j.vaccine.2019.06.008

31. Chen VCH, Wu SI, Huang KY, et al. Herpes zoster and dementia: A nationwide population-based cohort study. *J Clin Psychiatry* 2018;79:161132. https://doi.org/10.4088/JCP.16m11312

32. de Bree L, Koeven VACM, Joosten LAB, et al. Non-specific effects of vaccines: Current evidence and potential implications. *Semin Immunol* 2018;39:35-43. https://doi.org/10.1016/j.smim.2018.06.002

33. Aaby P, Benn CS, Flanagan KL, et al. The non-specific and sex-differential effects of vaccines. *Vaccine* 2020;20:464-70. https://doi.org/10.1016/j.vaccine.01577-020-0338-x

34. Izhaki RF, Lathe R, Balin BJ, et al. Microbes and Alzheimer’s disease. *J Alzheimer’s Dis* 2015;51:979-84. https://doi.org/10.3233/JAD-160152

35. Moor RD, Lathe R, Tanzi RE. The antimicrobial protection hypothesis of Alzheimer’s disease. *Alzheimer’s Dement* 2018;14:1602-14. https://doi.org/10.1016/j.jalz.2016.08.004

36. Schneeberger A, Hendrix S, Mandler M, et al. Results from a Phase II Study to Assess the Clinical and Immunological Activity of AFFITOPE® AD02 in Patients with Early Alzheimer’s Disease. Results from a Phase II Study to Assess Immunol Act AFFITOPE® AD02 Patients with Early Alzheimer’s Dis 2015;2:103-14. https://doi.org/10.14283/JPAD.160152

37. Schmader KE, Levin MJ, Gnann JW, et al. Efficacy, safety, and tolerability of herpes zoster vaccine Zostavax® in Stockholm County, Sweden. *J Inf Dis* 2020. https://doi.org/10.3233/JID-202142

38. Itzhaki RF, Lathe R, Balin BJ, et al. Herpes Simplex Virus and Alzheimer’s disease. *Intervntional evidence for a causal link. Lancet* 2000. https://doi.org/10.1097/00001908-199905280-00043

39. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. *Lancet Infect Dis* 2007;7:658-66.

40. Schnier C, Janbek J, Lathe R, Haas J. Reduced dementia incidence after varicella zoster vaccination in Wales 2013–2020. *Alzheimer’s Dement*. 2022;8:12293. https://doi.org/10.1002/trc.212293

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.